LKT Labs

Biochemicals for Life Science Research

MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.40 In stock
5 mg $218.70 In stock
10 mg $337.40 In stock
Bulk Quote

Quicklinks

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2
Purity

≥98%
Formula

C27H20ClFN4O4
Formula Wt.

518.92
IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
Synonym

Alisertib
Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble
Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF
Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • I7155

    Isoindigo

    Potential AhR binding agent.

    ≥98%
  • C0246

    Calcimycin

    Polyether pyrrole, divalent cation ionophore.

    ≥98%
  • A5170

    Amrinone

    Pyridine; PDE3 inhibitor.

    ≥98%
  • V574451

    Volitinib

    c-Met inhibitor.

    ≥98%
  • A488240

    AMG-337

    Selective inhibitor of c-Met.

    ≥99%
  • A6800

    AR-A014418

    GSK-3β inhibitor.

    ≥98%
  • A2500

    AG-1478

    EGFR inhibitor.

    ≥98%
  • P2002

    PF-04691502 Dihydrate

    PI3K and mTOR inhibitor.

    ≥98%
  • J889290

    JWH 133

    Cannabinoid receptor 2 selective agonist.

    ≥95%
  • M9356

    Myomodulin

    Proton pump inhibitor

    ≥95%
  • T2936

    Thioridazine Hydrochloride

    Piperadine phenothiazine; FIASMA, D1-5, histami...

    ≥98%
  • B022691

    Baricitinib

    Selective and reversible JAK inhibitor.

    ≥99%
  • C2845

    Levo-Chloramphenicol

    Protein translation inhibitor, peptidyl transfe...

    ≥98%
  • P0260

    Papain Inhibitor

    Peptide produced in tomato leaves; potential ca...

    ≥95%
  • A980005

    AZ-5104

    Inhibitor of EGFR.

    ≥98%
  • A5161

    Ampiroxicam

    Piroxicam prodrug, NSAID; COX-1/2 inhibitor.

    ≥98%
  • H9712

    (E)-4-Hydroxytamoxifen

    SERM.

    ≥97%
  • T982698

    L-Tyrosine disodium salt

    Amino acid precursor of dopamine.

    ≥98%
  • S7870

    Streptozocin

    Nitrosourea-amino sugar conjugate, DNA cross-li...

    ≥98%
  • N5778

    Notoginsenoside R1

    Triterpene saponin found in species of Panax.

    ≥98%